Overview

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

Status:
Completed

Trial end date:
2014-05-29

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GDC-0425 administered with and without gemcitabine.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Gemcitabine